Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26


Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin.

Hall JC, Marlow LA, Mathias AC, Dawson LK, Durham WF, Meshaw KA, Mullin RJ, Synnott AJ, Small DL, Krishna M, von Hoff D, Schüler J, Hart SN, Couch FJ, Colon-Otero G, Copland JA.

J Transl Med. 2016 May 10;14(1):129. doi: 10.1186/s12967-016-0875-z.


Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors.

Rheault TR, Caferro TR, Dickerson SH, Donaldson KH, Gaul MD, Goetz AS, Mullin RJ, McDonald OB, Petrov KG, Rusnak DW, Shewchuk LM, Spehar GM, Truesdale AT, Vanderwall DE, Wood ER, Uehling DE.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):817-20. doi: 10.1016/j.bmcl.2008.12.011. Epub 2008 Dec 7.


Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.

Molina JR, Kaufmann SH, Reid JM, Rubin SD, Gálvez-Peralta M, Friedman R, Flatten KS, Koch KM, Gilmer TM, Mullin RJ, Jewell RC, Felten SJ, Mandrekar S, Adjei AA, Erlichman C.

Clin Cancer Res. 2008 Dec 1;14(23):7900-8. doi: 10.1158/1078-0432.CCR-08-0415.


Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors.

Stevens KL, Alligood KJ, Alberti JG, Caferro TR, Chamberlain SD, Dickerson SH, Dickson HD, Emerson HK, Griffin RJ, Hubbard RD, Keith BR, Mullin RJ, Petrov KG, Gerding RM, Reno MJ, Rheault TR, Rusnak DW, Sammond DM, Smith SC, Uehling DE, Waterson AG, Wood ER.

Bioorg Med Chem Lett. 2009 Jan 1;19(1):21-6. doi: 10.1016/j.bmcl.2008.11.023. Epub 2008 Nov 13.


Formoterol fumarate and roxithromycin effects on muscle mass in an animal model of cancer cachexia.

Kenley RA, Denissenko MF, Mullin RJ, Story J, Ekblom J.

Oncol Rep. 2008 May;19(5):1113-21.


Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines.

Rusnak DW, Alligood KJ, Mullin RJ, Spehar GM, Arenas-Elliott C, Martin AM, Degenhardt Y, Rudolph SK, Haws TF Jr, Hudson-Curtis BL, Gilmer TM.

Cell Prolif. 2007 Aug;40(4):580-94.


Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.

Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, Hopper TM, Miller CG, Harrington LE, Onori JA, Mullin RJ, Gilmer TM, Truesdale AT, Epperly AH, Boloor A, Stafford JA, Luttrell DK, Cheung M.

Mol Cancer Ther. 2007 Jul;6(7):2012-21.


Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ.

Cancer Res. 2006 Feb 1;66(3):1630-9.


Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models.

Dev IK, Dornsife RE, Hopper TM, Onori JA, Miller CG, Harrington LE, Dold KM, Mullin RJ, Johnson JH, Crosby RM, Truesdale AT, Epperly AH, Hinkle KW, Cheung M, Stafford JA, Luttrell DK, Kumar R.

Br J Cancer. 2004 Oct 4;91(7):1391-8.


Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines.

Gaul MD, Guo Y, Affleck K, Cockerill GS, Gilmer TM, Griffin RJ, Guntrip S, Keith BR, Knight WB, Mullin RJ, Murray DM, Rusnak DW, Smith K, Tadepalli S, Wood ER, Lackey K.

Bioorg Med Chem Lett. 2003 Feb 24;13(4):637-40.


The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM.

Mol Cancer Ther. 2001 Dec;1(2):85-94.


Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.

Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL.

Oncogene. 2002 Sep 12;21(41):6255-63.


The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.

Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M, Smith KJ, Guntrip SB, Carter MC, Shaw RJ, Jowett A, Stables J, Topley P, Wood ER, Brignola PS, Kadwell SH, Reep BR, Mullin RJ, Alligood KJ, Keith BR, Crosby RM, Murray DM, Knight WB, Gilmer TM, Lackey K.

Cancer Res. 2001 Oct 1;61(19):7196-203.


Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843.

Wolfe LA, Mullin RJ, Laethem R, Blumenkopf TA, Cory M, Miller JF, Keith BR, Humphreys J, Smith GK.

Bioconjug Chem. 1999 Jan-Feb;10(1):38-48.


Effect of purine synthesis inhibition on WiDr spheroids in vitro or on WiDr or colon 38 tumors in vivo. Complete growth inhibition but not regression.

Jansen M, Dykstra M, Lee JI, Stables J, Topley P, Knick VC, Mullin RJ, Duch DS, Smith GK.

Biochem Pharmacol. 1994 Mar 15;47(6):1067-78.


Synthesis and biological evaluation of N alpha-(5-deaza-5,6,7,8-tetrahydropteroyl)-L-ornithine.

Singh SK, Singer SC, Ferone R, Waters KA, Mullin RJ, Hynes JB.

J Med Chem. 1992 May 29;35(11):2002-6.


In vivo antitumor activity and metabolism of a series of 5-deazaacyclotetrahydrofolate (5-DACTHF) analogues.

Mullin RJ, Keith BR, Bigham EC, Duch DS, Ferone R, Heath LS, Singer S, Waters KA, Wilson HR.

Biochem Pharmacol. 1992 Apr 1;43(7):1627-34.


A radiometric method for objectively screening large numbers of compounds against Pneumocystis carinii in vitro.

Comley JC, Mullin RJ, Wolfe LA, Hanlon MH, Ferone R.

J Protozool. 1991 Nov-Dec;38(6):144S-146S.


Microculture screening assay for primary in vitro evaluation of drugs against Pneumocystis carinii.

Comley JC, Mullin RJ, Wolfe LA, Hanlon MH, Ferone R.

Antimicrob Agents Chemother. 1991 Oct;35(10):1965-74.


Preparation of a chiral matrix. Resolution of (6R,S)-N5-formyltetrahydrofolate.

Mullin RJ, Duch DS.

J Chromatogr. 1991 Aug 30;555(1-2):254-9.


Activity of an NAD-dependent 5,10-methylenetetrahydrofolate dehydrogenase in normal tissue, neoplastic cells, and oncogene-transformed cells.

Smith GK, Banks SD, Monaco TJ, Rigual R, Duch DS, Mullin RJ, Huber BE.

Arch Biochem Biophys. 1990 Dec;283(2):367-71.


Direct demonstration of the active salvage of preformed purines by murine tumors.

Johnson DL, Mullin RJ, Duch DS, Benkovic SJ.

Biochem Biophys Res Commun. 1990 Aug 16;170(3):1164-9.


In vivo and in vitro metabolism of 5-deazaacyclotetrahydrofolate, an acyclic tetrahydrofolate analogue.

Hanlon MH, Ferone R, Mullin RJ, Keith BR.

Cancer Res. 1990 Jun 1;50(11):3207-11.


Distribution and metabolism of calcium leucovorin in normal and tumor tissue.

Mullin RJ, Keith BR, Duch DS.

Adv Exp Med Biol. 1988;244:25-38. No abstract available.


Vitamin C biosynthesis in prosimians: evidence for the anthropoid affinity of Tarsius.

Pollock JI, Mullin RJ.

Am J Phys Anthropol. 1987 May;73(1):65-70.


Isolation and characterization of beta- and gamma-caseins from horse milk.

Visser S, Jenness R, Mullin RJ.

Biochem J. 1982 Apr 1;203(1):131-9.

Supplemental Content

Loading ...
Support Center